Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has been assigned an average recommendation of “Hold” from the six ratings firms that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $23.00.
Several equities research analysts have issued reports on JNP shares. TheStreet raised shares of Juniper Pharmaceuticals from a “d+” rating to a “c” rating in a report on Wednesday, April 12th. BMO Capital Markets raised shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $31.00 to $34.00 in a report on Friday, July 14th. ValuEngine lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. HC Wainwright reissued a “hold” rating on shares of Juniper Pharmaceuticals in a report on Monday, May 15th. Finally, Roth Capital set a $12.00 price target on shares of Juniper Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, May 6th.
Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in Juniper Pharmaceuticals by 7.6% in the fourth quarter. Renaissance Technologies LLC now owns 254,300 shares of the specialty pharmaceutical company’s stock valued at $1,424,000 after buying an additional 17,900 shares during the last quarter. Acadian Asset Management LLC raised its stake in Juniper Pharmaceuticals by 6.6% in the first quarter. Acadian Asset Management LLC now owns 41,037 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 2,544 shares during the last quarter. Algert Global LLC raised its stake in Juniper Pharmaceuticals by 28.9% in the first quarter. Algert Global LLC now owns 108,315 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 24,270 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in Juniper Pharmaceuticals during the first quarter valued at $475,000. Finally, TFS Capital LLC raised its stake in Juniper Pharmaceuticals by 87.0% in the first quarter. TFS Capital LLC now owns 31,619 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 14,707 shares during the last quarter. 36.75% of the stock is currently owned by institutional investors and hedge funds.
Juniper Pharmaceuticals (NASDAQ JNP) opened at 4.65 on Tuesday. The firm has a market capitalization of $50.42 million, a price-to-earnings ratio of 8.23 and a beta of 0.28. Juniper Pharmaceuticals has a one year low of $3.65 and a one year high of $7.15. The firm’s 50-day moving average is $5.01 and its 200 day moving average is $4.74.
Juniper Pharmaceuticals (NASDAQ:JNP) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The firm had revenue of $13.96 million for the quarter, compared to analyst estimates of $11.84 million. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. Analysts forecast that Juniper Pharmaceuticals will post ($0.51) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Juniper Pharmaceuticals, Inc. (JNP) Receives Average Recommendation of “Hold” from Brokerages” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/10/analysts-set-juniper-pharmaceuticals-inc-jnp-target-price-at-23-00-updated-updated.html.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
